{
    "nct_id": "NCT06088888",
    "official_title": "A Single-arm, Open-label, Dose Escalation + Cohort Expansion Phase 1 Trial on Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Subjects with Refractory or Advanced Chronic Myelogenous Leukemia",
    "inclusion_criteria": "* Willing to participate in the study with informed consent;\n* At least 18 years of age at the time of screening;\n* Any sex;\n* Diagnosis of CML-CPduring the screening period;\n* Intolerant or resistant to TKI treatments;\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2;\n* Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels;\n* Adequate renal and liver function;\n* Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results;\n* Negative blood pregnancy test results for female patients of childbearing potential.\n* Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Exposure to other antineoplastic therapies prior to study enrollment;\n* Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy;\n* Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia);\n* Hematopoietic cell transplantation < 60 days prior to the first dose;\n* Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy;\n* Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment);\n* Exposure to drugs related to torsade de pointes;\n* Cytological or pathological diagnosis of active central nervous system disorder;\n* Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol;\n* Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome;\n* Uncontrolled hypertension;\n* Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose;\n* Severe hemorrhagic disorders unrelated to CML;\n* History of pancreatitis;\n* History of excessive alcohol use;\n* History of elevation in amylase or lipase within 1 year;\n* Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening;\n* Uncontrolled hypertriglyceridemia;\n* Malabsorption syndrome or other illness that could affect oral absorption.\n* Diagnosis of another primary malignancy in the past 3 years;\n* Reception of major surgery within 14 days prior to the first dose;\n* Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment;\n* Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections);\n* Have received or will receive a COVID-19 vaccine within 14 days of study enrollment;\n* Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening;\n* Pregnant or breastfeeding female;\n* Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug;\n* Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor;\n* Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;",
    "miscellaneous_criteria": ""
}